NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImmunOs Therapeutics

ImmunOs Therapeutics

Private
SchlierenHealthcare & Life Scienceshttps://www.immunostherapeutics.com/

Last Round

Series C

Sep 17, 2024

Total Funding Raised

$100.2M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ImmunOs Therapeutics is a biotechnology company that develops novel human immunomodulatory proteins and biologic therapies for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyhuman leukocyte antigenHLAfusion proteinsoncologycancer drugautoimmune diseasebiotechdrug discoveryprotein engineeringsolid tumorsbiopharmaclinical stagedrug pipelinenext-gen biologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunOs Therapeutics Comps

Public and private peers based on sector, stage, and business model.

ImmunOs Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ImmunOs Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 17, 2024
Series BJun 7, 2022
Series ADec 10, 2019
Series ASep 18, 2018

ImmunOs Therapeutics Investors

Notable investors and investment history

ImmunOs Therapeutics investors
InvestorRounds
BioMedPartnersSeries A, Series B, Series C
GL Capital GroupSeries B
GimvSeries B, Series C
PEAK6 Strategic CapitalSeries B
Fiscus DAOSeries B
PEAK6 InvestmentsSeries B
BioInnovation CapitalSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 84% MoM.

ImmunOs Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunOs Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunOs Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range12
Year Founded2014
Last FundingSep 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.